EXACT Therapeutics AS

OB:EXTX Voorraadrapport

Marktkapitalisatie: NOK 192.5m

EXACT Therapeutics Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Per Walday

Algemeen directeur

NOK 2.8m

Totale compensatie

Percentage CEO-salaris80.2%
Dienstverband CEO2.4yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn2.3yrs
Gemiddelde ambtstermijn bestuur5.1yrs

Recente managementupdates

Recent updates

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Aug 09
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

Apr 20
Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Sep 07
We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

May 06
We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Dec 30
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

Sep 15
Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

Jan 31
EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Aug 21
We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

May 21
We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

Analyse CEO-vergoeding

Hoe is Per Walday's beloning veranderd ten opzichte van EXACT Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-NOK 55m

Mar 31 2024n/an/a

-NOK 52m

Dec 31 2023NOK 3mNOK 2m

-NOK 48m

Sep 30 2023n/an/a

-NOK 42m

Jun 30 2023n/an/a

-NOK 36m

Mar 31 2023n/an/a

-NOK 38m

Dec 31 2022NOK 2mNOK 1m

-NOK 40m

Compensatie versus markt: De totale vergoeding ($USD 256.27K ) Per } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Norwegian markt ($USD 299.15K ).

Compensatie versus inkomsten: De vergoeding van Per is gestegen terwijl het bedrijf verliesgevend is.

CEO

Per Walday (64 yo)

2.4yrs

Tenure

NOK 2,833,302

Compensatie

Dr. Per Walday, Ph D., has been the Chief Executive Officer at PCI Biotech AS since 2008. He serves as Chief Executive Officer at EXACT Therapeutics AS since June 5, 2022.Dr. Walday had been the Chief Exe...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Per Walday
Chief Executive Officer2.4yrsNOK 2.83mgeen gegevens
Masha Paule Nathalie Stromme
Vice-Chair of the Board9.8yrsNOK 445.00kgeen gegevens
Svein Kvåle
Co Founder & COOno dataNOK 1.65m9.43%
NOK 18.1m
John Edminson
Chief Financial Officer2.1yrsNOK 2.02mgeen gegevens
Amir Snapir
Chief Medical Officer2.2yrsNOK 2.66mgeen gegevens
Caspar Foghsgaard
Chief Business Officerless than a yearNOK 250.00kgeen gegevens
Per Sontum
Founderno dataNOK 2.49m5.99%
NOK 11.5m
Ragnar Bendicksen
Vice President of Technology2.6yrsgeen gegevensgeen gegevens

2.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van EXTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Masha Paule Nathalie Stromme
Vice-Chair of the Board9.8yrsNOK 445.00kgeen gegevens
William Castell
Director6.8yrsNOK 275.00k1.05%
NOK 2.0m
Anders Wold
Chair of the Board2.9yrsNOK 510.00kgeen gegevens
Ann-Tove Kongsnes
Director3.4yrsNOK 260.00kgeen gegevens

5.1yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van EXTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).